[VM-26 and cytosine arabinoside in the treatment of acute refractory lymphoblastic leukemia in adults].
D000293:Adolescent; D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000627:therapeutic use*
D003561:Cytarabine; D013713:Teniposide; D001215:Asparaginase; D011034:Podophyllotoxin
VM-26 y arabinósido de citosina en el trataminento de la leucemia aguda linfoblástica resistente del adulto.